To include your compound in the COVID-19 Resource Center, submit it here.

Seres reports Phase Ib data for SER-287 in UC

Seres Therapeutics Inc. (NASDAQ:MCRB) reported that none of three SER-287 treatment regimens improved the secondary endpoint of clinical response rate compared to placebo in a double-blind, U.S. Phase Ib trial to treat ulcerative colitis. The company said it plans to meet with FDA to discuss

Read the full 456 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE